Infectious Diseases

Thermo Fisher Scientific has announced to invest a hefty amount worth USD 800 Million across pharma manufacturing and services. The company plans to expand its capabilities in pharma manufacturing and services in the coming two years, with USD 475 Million reserved for 2020.  The company has been acquiring several companies to fulfil its goal of providing valuable healthcare and ensure there is no shortage of medicines to patients. Recently, Thermo Fischer has acquired Qiagen NV- a Netherlands based pharma company, which was currently focused on developing a vaccine for COVID-19. The company, the last year, had also bought a CDMO – Brammer Biomanufacturingng...